Skip to main content

Table 1 Patient and tumour characteristic by p16 expression status

From: Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer

  p16 Negative p16 Positive  
Patient/Tumour Data No. % No. % p
Nº of patients 90 18  
Age, years    
   Median 59 57 NS
   Range 33-84 44-77  
Sex      
   Male 84 93 17 94 NS
   Female 6 7 1 6  
Current smokers      
   No 3 3 3 16  
   Yes 67 74 10 55 0.01
Unknown 20 23 5 29  
Alcohol consumption      
   No 10 11 3 16  
   Yes 57 63 10 55 NS
Unknown 23 26 5 29  
Performance status      
   ECOG 0 36 40 9 50 NS
   ECOG 1 43 48 8 44  
   ECOG 2 11 12 1 6  
Tumor site      
   Oral cavity 14 16 2 11 0.04
   Oropharynx 30 33 9 50  
   Larynx 36 40 2 11  
   Hypopharynx 10 11 5 28  
PCR - HPV status      
HR-HPV (16,18,51,58) 8 9 9 50  
LR-HPV (5,6) 2 2 1 5.5 0.0001
Unknown subtype 1 1 1 5.5  
Negative 79 88 7 39  
Grade      
   Well/Moderate 40 44 6 33 NS
   Poor 9 10 2 11  
   Unknown 41 46 10 56  
Tumour stage      
   T1-T3 37 41 5 28 NS
   T4 53 59 13 72  
Nodal status      
   No 28 31 5 28 NS
   N+ 62 69 13 72  
Stage      
III 28 31 6 33 NS
IV 62 59 12 67  
Treatment      
RT-CT 46 51 10 56 NS
RT-EGFR inhibitors 44 49 8 44  
Irradiation dose      
Mean 71   71.4   NS
Range 57-78   70-74   
Type of radiotherapy      
Conventional RT 11 12 0 0 NS
Concomitant boost 79 88 18 100  
Response      
Complete response 67 74 16 89  
Partial response 16 18 0 0 NS
Stable disease 1 1 1 5.5  
Progression 0 0 1 5.5  
Unknown 6 7 0 0  
Median OS (months) 32   54   NS
Range 14-50   20-87   
Median DFS (months) 18   52   NS
Range 13-24   0-103   
  1. Abbreviation: NS, not significant.